Studies show that FIT positivity thresholds can be lowered to increase sensitivity and specificity, which is similar to mt-sRNA testing.

Published Date: 12 Jun 2024

Without the extra testing, levels of sensitivity and specificity that are comparable to those reported for multitarget stool RNA (mt-sRNA) testing are obtained by lowering the fecal immunochemical test (FIT) positive threshold.

Read Full News

Latest News

Pancreatic Cysts: What’s the Actual Cancer Risk?

Pancreatic cysts are common and usually considered low risk — but even those lesions signal a significantly elevated and sustained cancer risk.

UTI Treatment Shift: Is Nitrofurantoin Coming Out on Top?

A large Spanish trial reports higher cure rates with 5-day nitrofurantoin therapy than with fosfomycin or pivmecillinam in women with uncomplicated UTIs.

Takeda Engaged in Antitrust Scheme to Delay Generic Constipation Drug, US Jury Finds

A U.S. jury on Monday found Takeda Pharmaceutical liable for causing about $885 million in damages by delaying a generic version of its constipation drug Amitiza through an...

Blood Proteins Link Poor Sleep to Increased Cancer Risk

Suboptimal sleep health, reflected in low sleep proteomic scores, is consistently associated with an increased risk for cancer, particularly gastrointestinal malignancies.

Housing Instability Tied to Lower Rates of CRC Screening

Unmet health-related social needs, especially housing instability and transportation barriers, are linked to lower rates of screening for colorectal cancer among US adults.

Olanzapine Cuts Radiation-Induced Nausea

The drug, widely used for chemotherapy-related nausea, may also be highly effective for symptoms caused by abdominal-pelvic radiotherapy.

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Latest News

Pancreatic cysts are common and usually considered low risk — but even those lesions signal a significantly elevated and sustained cancer risk.

A large Spanish trial reports higher cure rates with 5-day nitrofurantoin therapy than with fosfomycin or pivmecillinam in women with uncomplicated UTIs.

A U.S. jury on Monday found Takeda Pharmaceutical liable for causing about $885 million in damages by delaying a generic version of its constipation drug Amitiza through an...

Suboptimal sleep health, reflected in low sleep proteomic scores, is consistently associated with an increased risk for cancer, particularly gastrointestinal malignancies.

Unmet health-related social needs, especially housing instability and transportation barriers, are linked to lower rates of screening for colorectal cancer among US adults.

The drug, widely used for chemotherapy-related nausea, may also be highly effective for symptoms caused by abdominal-pelvic radiotherapy.

News All Time

Clinical Pearls to Advance Multidisciplinary Team-Based Care for Patients With GEP-NETs

Clinical Pearls to Advance Multidisciplinary Team-Based Care for Patients With GEP-NETs

Navigating the Future of Upper GI Cancer Treatment: Mechanisms, Personalization, and Expert Insights

Navigating the Future of Upper GI Cancer Treatment: Mechanisms, Personalization, and Expert Insights

Checkpoint, Claudin, and Beyond: Optimizing Biomarker-Driven Decisions in Advanced/Metastatic G/GEJ Cancer Care

Checkpoint, Claudin, and Beyond: Optimizing Biomarker-Driven Decisions in Advanced/Metastatic G/GEJ Cancer Care

EASL: European Association for the Study of the Liver

ACG: American College of Gastroenterology

AASLD: American Association for the Study of Liver Diseases

AASLD Video Pearls: Video Pearls from the American Association for the Study of Liver Diseases

CCC: Crohn's & Colitis Congress

Multiple Drugs Flagged for Higher C. Diff Risk

Increased risks observed for analgesics and corticosteroids, among others, in Swedish study

Dulaglutide or Tirzepatide? Worldwide Biopharma Changes

Also in TTHealthWatch: how treatments for hepatitis C have been used

Raw Dairy Farm Recalls Cheese Products as FDA Investigates E. Coli Outbreak

The company initially refused to recall the products

Is Surveillance Colonoscopy Needed for Elderly Patients With Adenomas?

Study finds deaths from other causes far surpass colorectal cancer diagnosis, death

Gaslighting in Gastro Care; Antidepressants and IBS Mortality; Diverticulitis Season

News and commentary from the world of gastroenterology and hepatology

Is Kissing for Celiacs Gluten-Free? Study Weighs In

Small trial finds little in the way of gluten transfer when celiac and non-celiac partners kiss

Strategy Reduces Inappropriate Proton Pump Inhibitor Use

Patient- and physician-facing interventions together doubled the reductions in PPI use

1.8 Billion MASLD Cases; Improving HCC Surveillance; Ultrasound for Crohn's Disease

News and commentary from the world of gastroenterology and hepatology

Recommended News For You

From Pathology to Precision: The Story of Leukemia Therapy

Daily physical activity, even at light intensities, linked to lower cancer risk

The Risk of Major Mortality is Associated with the Start of Opioids in Dementia.

Major Shifts in Urothelial Cancer Care: Immunotherapy Redefines Standards

Researchers have determined that malignancy hibernation will be the next front in the fight against breast cancer.

Chemicals in Sewage Sludge Fertilizer Pose Cancer Risk, EPA Says

Study finds common genetic target may halt breast cancer cell growth

Recommended Articles For You

Cancer Staging: Updates, Clinical Insights, and Educational Resources for Medical Professionals 

Unraveling the Mysteries of Lymphoma: A Journey into the Unknown 

Understanding Neutrophilia: Causes, Symptoms, and Treatment Options 

Therapeutic Innovations Through Germline Predisposition in Acute Leukemias and Myeloid Neoplasms 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Examines Office-Based Transperineal Prostate Biopsies Methodology.

2.

A global study demonstrates that screening for lung cancer significantly raises the long-term survival rate.

3.

Is a $2,000 Whole-Body MRI Worth It?

4.

Surgery may not be necessary to treat invasive breast cancer

5.

Limited Benefit from New Drugs; Significant Increase in Drug Prices; AI Boost for Mammo Results.

1.

Understanding Evans Syndrome: Causes, Symptoms, and Treatment Options 

2.

Understanding Sepsis and Precision-Medicine-Based Immunotherapy: A Pathophysiological Perspective

3.

Exploring The Science Of Hematopoietic Stem Cell Transplantation: What You Need To Know

4.

Unlocking the Secret to Accurate ANC Calculation with This Informative Blog Post

5.

Understanding Lymphedema: Symptoms, Causes, and Treatment 

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI

2.

Rates of CR/CRi and MRD Negativity in Iontuzumab-Treated Patients

3.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II

4.

First-Line Maintenance Therapy for Metastatic Urothelial Carcinoma: Bridging Clinical Practice and Trials

5.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot